HomeComparePFE vs NDAQ

PFE vs NDAQ: Dividend Comparison 2026

PFE yields 6.20% · NDAQ yields 1.29%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NDAQ wins by $90.2K in total portfolio value
10 years
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →
NDAQ
NDAQ
● Live price
1.29%
Share price
$83.52
Annual div
$1.08
5Y div CAGR
62.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$141.3K
Annual income
$64,247.81
Full NDAQ calculator →

Portfolio growth — PFE vs NDAQ

📍 NDAQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPFENDAQ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PFE + NDAQ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PFE pays
NDAQ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
NDAQ
Annual income on $10K today (after 15% tax)
$109.91/yr
After 10yr DRIP, annual income (after tax)
$54,610.64/yr
At 15% tax rate, NDAQ beats the other by $31,481.68/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PFE + NDAQ for your $10,000?

PFE: 50%NDAQ: 50%
100% NDAQ50/50100% PFE
Portfolio after 10yr
$96.2K
Annual income
$45,729.17/yr
Blended yield
47.54%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NDAQ right now

PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
NDAQ
Analyst Ratings
23
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$113.60
+36.0% upside vs current
Range: $108.00 — $120.00
Altman Z
2.5
Piotroski
9/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PFE buys
0
NDAQ buys
0
No recent congressional trades found for PFE or NDAQ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPFENDAQ
Forward yield6.20%1.29%
Annual dividend / share$1.72$1.08
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR13.2%62.3%
Portfolio after 10y$51.1K$141.3K
Annual income after 10y$27,210.54$64,247.81
Total dividends collected$60.1K$114.0K
Payment frequencyquarterlyquarterly
SectorHealthcareFinancials
Analyst consensusHoldBuy
Analyst price target$27.50$113.60

Year-by-year: PFE vs NDAQ ($10,000, DRIP)

YearPFE PortfolioPFE Income/yrNDAQ PortfolioNDAQ Income/yrGap
1← crossover$9,161$701.38$10,910$209.87$1.7KNDAQ
2$8,610$859.79$12,021$347.30$3.4KNDAQ
3$8,366$1,081.25$13,443$580.44$5.1KNDAQ
4$8,483$1,405.66$15,368$984.57$6.9KNDAQ
5$9,084$1,907.24$18,151$1,707.33$9.1KNDAQ
6$10,418$2,732.78$22,481$3,058.70$12.1KNDAQ
7$13,007$4,193.56$29,800$5,746.07$16.8KNDAQ
8$18,010$7,005.87$43,440$11,553.61$25.4KNDAQ
9$28,216$12,979.89$72,027$25,545.86$43.8KNDAQ
10$51,081$27,210.54$141,316$64,247.81$90.2KNDAQ

PFE vs NDAQ: Complete Analysis 2026

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →

NDAQFinancials

Nasdaq, Inc. operates as a technology company that serves capital markets and other industries worldwide. The Market Technology segment includes anti financial crime technology business, which offers Nasdaq Trade Surveillance, a SaaS solution for brokers and other market participants to assist them in complying with market rules, regulations, and internal market surveillance policies; Nasdaq Automated Investigator, a cloud-deployed anti-money laundering tool; and Verafin, a SaaS technology provider of anti-financial crime management solutions. This segment also handles assets, such as cash equities, equity derivatives, currencies, interest-bearing securities, commodities, energy products, and digital currencies. The Investment Intelligence segment sells and distributes historical and real-time market data; develops and licenses Nasdaq-branded indexes and financial products; and provides investment insights and workflow solutions. The Corporate Platforms segment operates listing platforms; and offers investor relations intelligence and governance solutions. As of December 31, 2021, it had 4,178 companies listed securities on The Nasdaq Stock Market, including 1,632 listings on The Nasdaq Global Select Market; 1,169 on The Nasdaq Global Market; and 1,377 on The Nasdaq Capital Market. The Market Services segment includes equity derivative trading and clearing, cash equity trading, fixed income and commodities trading and clearing, and trade management service businesses. This segment operates various exchanges and other marketplace facilities across various asset classes, which include derivatives, commodities, cash equity, debt, structured products, and exchange traded products; and provides broker, clearing, settlement, and central depository services. The company was formerly known as The NASDAQ OMX Group, Inc. and changed its name to Nasdaq, Inc. in September 2015. Nasdaq, Inc. was founded in 1971 and is headquartered in New York, New York.

Full NDAQ Calculator →
📬

Get this PFE vs NDAQ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PFE vs JNJPFE vs MRKPFE vs ABBVPFE vs BMYPFE vs LLYPFE vs SCHDPFE vs JEPIPFE vs O

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.